Real-World Outcomes in Patients With Relapsed-Refractory Multiple Myeloma (RRMM) With Prior Proteasome Inhibitor and Lenalidomide Exposure in Sweden

被引：0

作者：

Luong, Vincent ^{[1
,2
]}

Kashif, Muhammad ^{[1
]}

Uttervall, Katarina ^{[1
,2
]}

Bohlin, Anna ^{[1
]}

Fernstrom, Annette Oster ^{[1
]}

Qu, Ying ^{[3
]}

Lee, Seina ^{[4
]}

Mendes, Joao ^{[5
]}

Van Hoorenbeeck, Sandra ^{[6
]}

Franck, Eva Hellqvist ^{[3
]}

He, Jianming ^{[7
]}

Alici, Evren ^{[1
,2
]}

Lund, Johan ^{[1
,2
]}

机构：

[1] Karolinska Inst, Ctr Hematol & Regenerat Med, Dept Med, Solna, Sweden

[2] Karolinska Univ Hosp, Dept Hematol, Solna, Sweden

[3] Janssen Cilag AB, Stockholm, Sweden

[4] Janssen Res & Dev, Raritan, NJ USA

[5] Janssen Cilag Farmaceut, Sao Paulo, Brazil

[6] Janssen Cilag NV, Beerse, Belgium

[7] Janssen Global Serv LLC, Raritan, NJ USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-407

引用

页码：S269 / S270

页数：2